Investor FAQs

Where is the company’s head office located?
Covalon Technologies Ltd.’s head office is located at 1660 Tech Avenue, Unit 5, Mississauga, Ontario, Canada, L4W 5S7.
Where is the company incorporated?
Covalon Technologies Ltd. is incorporated in Canada.
When did Covalon Technologies Ltd. go public?
Covalon Technologies Ltd. was founded in 1999 and subsequently went public in 2004.
What is Covalon Technologies Ltd.’s fiscal year?
Covalon Technologies Ltd.’s fiscal year ends September 30.
How is the company’s stock traded?
Covalon Technologies Ltd. is traded on the TSX Venture Exchange (symbol: COV) and OTC Markets (symbol: CVALF).
Does Covalon Technologies Ltd. pay dividends?
Covalon Technologies Ltd. does not pay a dividend at this time.
Who is Covalon Technologies Ltd.'s transfer agent?
Covalon Technologies Ltd.’s transfer agent is TSX Trust (TMX Group).
Whom do I contact with questions about my stock?

For questions about your stock, please contact Brian Pedlar (bpedlar@covalon.com) or Danny Brannagan (dbrannagan@covalon.com).

Does the company have a direct stock purchase plan?
No, Covalon Technologies Ltd. does not have a direct stock purchase plan.
Who is the company’s auditor?
Covalon Technologies Ltd.’s auditor is PricewaterhouseCoopers LLP.
What does the company do?
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures.
What is the company’s business model?
Covalon Technologies Ltd. leverages its patented medical technology platforms and expertise in two ways: (i) we develop products that we sell under Covalon’s name; and (ii) we develop and commercialize medical products for other medical companies under development and license contracts.
How does the company generate revenue?

The majority of Covalon-branded products are sold through independent distributors to various health care providers such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians’ offices. Many of Covalon’s products require regulatory clearances and are sold on a prescription basis in the United States, Canada, the Middle East, Latin America, Asia, and a number of other international countries.

Covalon also licenses its technologies and products to large medical device companies and niche start-ups to create novel technology to advance our product offerings in various medical device markets. Covalon has worked with over twenty medical companies, including leaders in vascular access devices, I.V. infusion, orthopedics, device and patient care distributors, wound care product companies, specialty medical device manufacturers and major contract manufacturers.

Does the company own any intellectual property?
Covalon Technologies Ltd. currently has three proprietary platform technologies that have the potential to be developed into dozens of medical devices: (i) Biological matrix; (ii) Antimicrobial silicone adhesive; and (iii) Medical Coating technology. These platform technologies are protected by patents, patent applications and patents pending, patented and proprietary manufacturing processes, trade secrets, brands, trademarks, and trade names.
What is the company’s Biological Matrix technology?
Covalon Technologies Ltd.’s patented Biological Matrix platform is used to manufacture a family of products that treat chronic and infected wounds including diabetic ulcers (including diabetic foot ulcers), pressure ulcers, venous ulcers (including venous leg ulcers), donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. These dressings begin from a biological collagen base, which is generally biocompatible with the human body, and enable the release of beneficial materials, such as antimicrobials, into the wound site and/or enhance the removal of undesirable materials, such as wound exudate from the wound. Covalon’s patented manufacturing process for creating our biological matrix results in products that have certain clinical advantages over other dressings, such as open binding sites for destructive enzymes, effective antimicrobial activity, and exudate management properties that help chronic wounds heal.
What is the company’s Antimicrobial Silicone Adhesive technology?
Covalon Technologies Ltd.’s patent-pending antimicrobial silicone adhesive platform is the basis for a family of pre-surgical, post-surgical and vascular access products that are designed to kill 99.99% or more of any bacteria or yeast that comes into contact with the antimicrobial silicone. The Company’s Antimicrobial Silicone Adhesive platform is unique because the silicone adhesive contains both silver and chlorhexidine which provides broad-spectrum antimicrobial activity for a minimum of 7 days, while maintaining the beneficial properties of a silicone adhesive. Our technology meets or exceeds the current United States Food and Drug Administration’s “greater than 4 log reduction” standard for an antimicrobial claim against bacteria, and yeast, most commonly associated with healthcare acquired infections. The soft silicone adhesive also provides greater patient comfort, does not macerate or damage the skin, and was shown to be up to 10 times less painful upon removal when compared to acrylic adhesives, which are commonly used in medical products containing adhesives.
What is the company’s Medical Coating technology?
A highly versatile coating, CovaCoat® is a photochemical process that enables permanent covalent attachment of the coating to a wide variety of medical devices. Each formulation is specifically tailored to the device, and can be engineered to improve lubricity, hemocompatibility, infection prevention and controlled delivery of active pharmaceutical ingredients (APIs).
Where can I find out more about the company?

You can learn more about Covalon Technologies Ltd. by visiting the corporate website www.covalon.com.

Where can I get the company’s latest corporate news releases and financial reports?
Please visit the email alerts page and fill out the web form to be added to the distribution list.
How can I view the company’s financial results?

Quarterly and annual reports and other investor materials, when available, can be found on the SEDAR Filings page. Additionally, all filings can be accessed directly from the website, www.sedar.com.

Who makes up the company’s Executive Management team and Board of Directors?

Please visit the corporate governance section to view Covalon Technologies Ltd.’s Executive Management Team and Board of Directors.

How can I obtain further information or materials on the company’s innovative products?

For more information about products please visit the Products section of Covalon Technologies Ltd.’s corporate website.

Is there a way to receive instant updates regarding the date and times of financial releases and important events?

Please visit the email alerts page and fill out the web form to be added to the distribution list.

When is your next earnings release scheduled? How can I receive email updates for this information?

Covalon Technologies Ltd., reports financial results on a quarterly basis. For more information about financial releases and upcoming events please visit the “News and Events” page of “Investor Relations” section of our corporate website. Please visit the email alerts page and fill out the web form to be added to the distribution list.

How can I obtain a copy of your annual report and proxy?

A copy of the annual report and proxy are mailed out to shareholders of record on a yearly basis. The prior year’s annual report and proxy can be found in “Quarterly Results” in the “Financial Info” of the “Investor Relations” section of our corporate website. Additionally, all filings can be accessed directly from the website www.sedar.com.

Whom should I contact regarding investor inquiries?
Brian Pedlar bpedlar@covalon.com or Danny Brannagan dbrannagan@covalon.com.